Interferon Treatment in Hemodialysis Patients With Chronic Hepatitis C Virus Infection: A Systematic Review of the Literature and Meta-analysis of Treatment Efficacy and Harms

American Journal of Kidney Diseases

Volumn 51, Issue 2, 2008, Pages 263-277

  Gordon, Craig E ^a   Uhlig, Katrin ^a   Lau, Joseph ^a   Schmid, Christopher H ^b   Levey, Andrew S ^a   Wong, John B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b Institute for Clinical Research and Health Policy Studies   (United States)

Author keywords

hemodialysis; Hepatitis C virus; interferon; meta analysis; sustained virological response

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA;

ACUTE CHOLECYSTITIS; ACUTE PANCREATITIS; ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BONE PAIN; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONFUSION; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; GRAFT REJECTION; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MONOTHERAPY; PERICARDITIS; PNEUMONIA; SEIZURE; SEPSIS; SIDE EFFECT; SUDDEN DEATH; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEMODIAFILTRATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 38149112549     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.11.003     Document Type: Article

References (57)

1. World Health Organization. Hepatitis C-Global prevalence (update). Wkly Epidemiol Rec 49 (1999) 4-5 December
2. Fissell R.B., Bragg-Gresham J.L., Woods J.D., et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 65 (2004) 2335-2342
3. Huraib S., al-Rashed R., Aldrees A., Aljefry M., Arif M., and al-Faleh F.A. High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: A need for new dialysis strategies. Nephrol Dial Transplant 10 (1995) 470-474
4. Fabrizi F., Martin P., Dixit V., Bunnapradist S., and Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 20 (2004) 1271-1277
5. Kalantar-Zadeh K., Kilpatrick R.D., McAllister C.J., et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18 (2007) 1584-1593
6. Fabrizi F., Martin P., Dixit V., Bunnapradist S., and Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 5 (2005) 1452-1461
7. Watanabe H., Saito T., Shinzawa H., et al. Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study. J Med Virol 71 (2003) 56-61
8. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358 (2001) 958-965
9. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
10. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 40 suppl 5 (2005) S336-S338
11. Marcellin P., Boyer N., Gervais A., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 127 (1997) 875-881
12. Reichard O., Glaumann H., Fryden A., Norkrans G., Wejstal R., and Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 30 (1999) 783-787
13. Yoshida H., Shiratori Y., Moriyama M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
14. Bruno S., Battezzati P.M., Bellati G., et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 34 (2001) 748-755
15. Yoshida H., Arakawa Y., Sata M., et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 123 (2002) 483-491
16. Fabrizi F., Dulai G., Dixit V., Bunnapradist S., and Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 18 (2003) 1071-1081
17. Russo M.W., Goldsweig C.D., Jacobson I.M., and Brown Jr. R.S. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 98 (2003) 1610-1615
18. Urbanek P., Tesar V., Prochazkova-Francisci E., Lachmanova J., Marecek Z., and Svobodnik A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood Purif 22 (2004) 344-350
19. Gursoy M., Gur G., Arslan H., Ozdemir N., and Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat 8 (2001) 70-77
20. Vogel W., Graziadei I., Umlauft F., et al. High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci 41 suppl (1996) S81-S85
21. Sporea I., Popescu A., Sirli R., et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 12 (2006) 4191-4194
22. Russo M.W., Ghalib R., Sigal S., and Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 21 (2006) 437-443
23. Kokoglu O.F., Ucmak H., Hosoglu S., et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 575-580
24. Beld M., Sentjens R., Rebers S., et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, version 2.0, assay. J Clin Microbiol 40 (2002) 788-793
25. Konnick E.Q., Erali M., Ashwood E.R., and Hillyard D.R. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol 40 (2002) 768-773
26. Pawlotsky J.M. Use and interpretation of virological tests for hepatitis C. Hepatology 36 5 suppl (2002) S65-S73
27. Zeuzem S., Heathcote E.J., Shiffman M.L., et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol 39 (2003) 106-111
28. Koenig P., Vogel W., Umlauft F., et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 45 (1994) 1507-1509
29. McHutchison J.G., Gordon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
30. Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
31. Huraib S., Iqbal A., Tanimu D., and Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 21 (2001) 435-440
32. Campistol J.M., Esforzado N., Martinez J., et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 14 (1999) 2704-2709
33. Fernandez J.L., Rendo P., del Pino N., and Viola L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J Viral Hepat 4 (1997) 113-119
34. Benci A., Caremani M., Menchetti D., Sasdelli M., and Giusti P.B. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr Med Res Opin 14 (1998) 141-144
35. Buargub M., El Huni S., and Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi J Kidney Dis Transpl 17 (2006) 338-343
36. Casanovas-Taltavull T., Baliellas C., Benasco C., et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: Results after transplantation. Am J Gastroenterol 96 (2001) 1170-1177
37. Chan T.M., Wu P.C., Lau J.Y., Lok A.S., Lai C.L., and Cheng I.K. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 12 (1997) 1414-1419
38. Degos F., Pol S., Chaix M.L., et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 16 (2001) 1017-1023
39. Espinosa M., Rodriguez M., Martin-Malo A., et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 55 (2001) 220-226
40. Hanrotel C., Toupance O., Lavaud S., et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88 (2001) 120-126
41. Huraib S., Tanimu D., Romeh S.A., et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 34 (1999) 55-60
42. Izopet J., Rostaing L., Moussion F., et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 176 (1997) 1614-1617
43. Kamar N., Toupance O., Buchler M., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14 (2003) 2092-2098
44. Mousa D.H., Abdalla A.H., Al-Shoail G., Al-Sulaiman M.H., Al-Hawas F.A., and Al-Khader A.A. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 36 (2004) 1831-1834
45. Okuda K., Hayashi H., Yokozeki K., Kondo T., Kashima T., and Irie Y. Interferon treatment for chronic hepatitis C in haemodialysis patients: Suggestions based on a small series. J Gastroenterol Hepatol 10 (1995) 616-620
46. Ozdemir F.N., Akcay A., Sezer S., et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 26 (2004) 583-588
47. Pol S., Thiers V., Carnot F., et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 47 (1995) 1412-1418
48. Raptopoulou-Gigi M., Spaia S., Garifallos A., et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 10 (1995) 1834-1837
49. Rocha C.M., Perez R.M., Ferreira A.P., et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 26 (2006) 305-310
50. Rendina M., Schena A., Castellaneta N.M., et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 46 (2007) 768-774
51. Deltenre V., Canva F., Provot F., et al. Pegylated interferon and ribavirin in haemodialyzed patients with chronic hepatitis C: A prospective study. Hepatology 44 suppl (2006) S329A
52. Zeuzem S., Teuber G., Naumann U., et al. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 32 (2000) 835-841
53. Rostaing L., Chatelut E., Payen J.L., et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J Am Soc Nephrol 9 (1998) 2344-2348
54. Jafar T.H., Schmid C.H., Landa M., et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 (2001) 73-87
55. Dickersin K., Min Y.I., and Meinert C.L. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 267 (1992) 374-378
56. Terrin N., Schmid C.H., and Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 58 (2005) 894-901
57. Kasiske B.L. Meta-analysis as a clinical tool in nephrology. Kidney Int 53 (1998) 819-825